Stilla Technologies–Dangla R: management, 202402– CEO before CTO before CEO + Founder since 2013

	Period	2024-02-01
	Predecessor	Stilla Technologies–Dangla R: management, 202101– CTO before CEO + Founder since 2013
	Organisation	Stilla Technologies SAS
	Group	Stilla Technologies (Group)
	Product	digital PCR technology (dPCR)
	Product 2	Nio™+ digital PCR instrument
	Person	Dangla, Rémi (Stilla Technologies 202402– CEO before CTO before CEO + Founder since 2013)

Stilla Technologies SAS. (2/22/24). "Press Release: Stilla Technologies Closes $26.5M Series C Financing to Accelerate Commercialization of Its Digital PCR Platform – Expands Leadership team". Paris & Boston, MA.

> Financing led by CLIIF, with its investors Yuzi Investment Holding Group (Yuzi) and Tus-Holdings, with participations from existing investors and business angel investors.

> Funding leveraged to accelerate the commercialization of the recently launched Nio™+ system to a market leading position for routine digital PCR applications such as Biopharma, Applied Testing and Clinical.

> Founder named CEO; new VP of Global Marketing, General Manager for North America & CFO appointed.

Today, Stilla Technologies, the start-up leading innovations in digital PCR, announced it has closed a $26.5 million Series C financing. The financing was led by a the venture fund CLIFF with its main investors Yuzi Investment Holding Group (Yuzi) and Tus-Holdings, together with the participation of existing investors Illumina Ventures, Kurma Partners, PSSF, IdInvest, BNP Paribas Development and LBO France.

Concurrent to this financing, Liu Sisi, General Manager of Zhongyu Equity Investment Co. Ltd., a subsidiary of Yuzi, joins the board of directors representing Yuzi.

“We see great potential of Stilla’s expertise and solution in the Chinese market,” said Liu Sisi. “Yuzi is building its Life Science investment group in Central China, with the resources and network including key hospitals, academies and industrial partners. We will work closely with Stilla in setting up a Joint Venture in our region to utilize this network and support it to be the leading digital PCR platform in China.”

The funding received will be primarily used to scale Stilla’s marketing and sales channels and accelerate the commercialization of Stilla’s innovative portfolio of digital PCR solutions, in particular of its recently launched “all-in-one” Nio™+ instrument. With the Nio™+ instrument, Stilla brings to market a solution designed, built and field tested to answer the needs of a digital PCR market maturing into routine testing: full integration of the digital PCR workflow into one compact instrument, high throughput, random access and automation, combined the Stilla’s signature ultimate multiplexing capabilities of up to 28 targets per assay.

Shortly after the Series C closing, Stilla Technologies has reinforced its leadership team. Rémi Dangla, founder of Stilla Technologies, has been named as President and Chief Executive Officer after having led the successful development of Nio™+ for the last 2 years.

The executive team of the Company also welcomes Afif Abdel Nour as VP of Global Marketing; Kerri McWeeny as General Manager for North America; and Puyu Li as Chief Financial Officer. Dr. Afif Abdel Nour has committed his professional endeavors to expanding PCR’s presence within the realm of Life Sciences & Diagnostics. His tenure at Bio-Rad marked the inception of this journey, followed by a prominent role in spearheading the strategic marketing initiatives for Qiagen’s digital PCR portfolio. Kerri McWeeny has held marketing and commercial leadership positions at Illumina and Jumpcode Genomics, bringing extensive knowledge regarding the North American genomics market to Stilla. Puyu Li has been CFO in the VC industry for 20 years at Partech in France and at Sinovation Ventures in China and she will support the Company’s worldwide development, in particular in China.

In addition, the board of directors welcomes Dr. Gabriel Festoc, former President of Polyplus, as an independent director. Gabriel brings valuable experience in successfully building and growing companies in the PCR as well as Biopharma industry.

“For over 10 years, Stilla has been answering the market’s demands for the ability to transform complex genomic data into actionable insights over a breadth of applications, be it cancer and liquid biopsy testing, cell and gene therapy, infectious disease detection, or food and environmental testing,” said Rémi Dangla. “I’m excited to be able to lead an organization that has consistently delivered the most innovative solutions by pushing technological boundaries while also expanding the accessibility of genetic testing into all types of laboratories all over the globe.”

About Stilla Technologies

Stilla Technologies is the digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking solutions, include the industry’s first digital PCR systems to feature three, six, and seven fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA.

To learn more, visit www.stillatechnologies.com.